BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 14
• 15
• 16
• 17
• 18
• 21
• 22
• 23
• 27
• 28
• 29
• 30

• Drug Development

  Celldex Presents Data On New Product Candidate, CDX-1140, A Novel CD40 Agonist Antibody

  November 14, 2016

   · 

  5 min read
• Drug Development

  New Study Demonstrates Anti-Tumor Advantages For Combination Treatment Featuring Peregrine’ PS-Targeting Antibodies In A Preclinical Melanoma Model

  November 14, 2016

   · 

  10 min read
• Pharm Country

  Actinium Announces Notice Of Allowance For U.S. Patent Related To Actimab-A

  November 14, 2016

   · 

  4 min read
• Drug Development

  Horizon Pharma Presents Data On KRYSTEXXA (Pegloticase) For The Management Of Refractory Chronic Gout At The 2016 ACR/ARHP Annual Meeting

  November 14, 2016

   · 

  10 min read
• Drug Development

  Amgen Release: Results From Phase 3 BRIDGE Study Show Romosozumab Significantly Increases Bone Mineral Density In Men With Osteoporosis

  November 14, 2016

   · 

  14 min read
• Treatments Commence Using UAE’s First Varian Medical Systems TrueBeam System

  November 14, 2016

   · 

  3 min read
• Genetown

  American Association for Study of Liver Diseases Release: Number Of Hepatitis B-Related Liver Transplants Drops While Hepatitis B-Related Liver Cancer Continues To Rise

  November 14, 2016

   · 

  5 min read
• Drug Development

  Boston Biomedical Announces Orphan Drug Designation For Napabucasin In Pancreatic Cancer

  November 14, 2016

   · 

  5 min read
• Drug Development

  Braeburn Pharma And Camurus Announce Positive Top-Line Phase 3 Results For Long-Acting Buprenorphine (CAM2038) For Treatment Of Opioid Addiction

  November 14, 2016

   · 

  13 min read
• BioMidwest

  Eight Weeks Of Treatment With AbbVie’s Investigational, Pan-Genotypic Regimen Of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR Rates Across All Major Genotypes Of Chronic Hepatitis C

  November 14, 2016

   · 

  7 min read